Search - tctmd.com

Displaying 141 - 160 of 329

Sort: Relevancy | Date

Presentation TCT 2017

Options for Aortic Stenosis and Prosthesis-Patient Mismatch: Reoperation, Fracture, Supra-annular Valve, Balloon Valvuloplasty, Other

Presenter: Alfredo Trento, David J. Cohen

November 01, 2017

Presentation TCT 2017

Identifying the Futile Severe AS Patient - Who Shouldnt Be Treated With TAVR?

Presenter: Bernard Prendergast, Brian K. Whisenant, David J. Cohen

November 01, 2017

News Conference News TCT 2017

VAMPIRE 3: Attenuated Plaque May Signal Benefit of Thrombus Removal in PCI

Shelley Wood

November 01, 2017

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

Presentation TCT 2017

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Presenter: Patrick W. Serruys, David J. Cohen

October 31, 2017

News Conference News TCT 2017

Live From Denver: TCT 2017, Day Two

Shelley Wood

October 31, 2017

News Conference News TCT 2017

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

Michael O'Riordan

October 30, 2017

News Conference News TCT 2017

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Todd Neale

October 30, 2017

Presentation TCT 2017

Case #5: Tamponade in the Post-CABG Patient (With Discussion)

Presenter: Mauricio G. Cohen, Simon R. Dixon, David Daniels

October 30, 2017

News Conference News TCT 2017

Live From Denver: TCT 2017, Day One

Shelley Wood

October 30, 2017

News Conference News TCT 2017

No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy

Michael O'Riordan

October 30, 2017

Podcast

Episode 16: Healthcare Reform, Embolic Protection in TAVR, and More

August 10, 2017

Presentation TVT 2017

Is the Current Practice of Watchful Waiting in Severe AS a Viable Strategy in the Future?

Presenter: David J. Cohen, Jeffrey J. Popma, Robert O. Bonow

June 16, 2017

Presentation TVT 2017

Rationale and Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Presenter: David J. Cohen, Jeffrey J. Popma, Philippe Généreux

June 16, 2017

Presentation TVT 2017

Rationale and Status Update of the TAVR UNLOAD Trial Moderate AS Patients With Reduced Ejection Fraction

Presenter: David J. Cohen, Jeffrey J. Popma, Nicolas M. Van Mieghem

June 16, 2017

Presentation TVT 2017

A Practical Clinical Algorithm for Correctly Diagnosing and Managing Patients With Low Flow Aortic Stenosis

Presenter: David J. Cohen, Jeffrey J. Popma, Howard C. Herrmann

June 16, 2017

Presentation TVT 2017

A Model of TAVR (vs SAVR) Case Selection, Based Solely on Clinical and Anatomic Factors

Presenter: David J. Cohen, Jeffrey J. Popma, Martin B. Leon

June 16, 2017

Presentation TVT 2017

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

Presenter: David J. Cohen, Jeffrey J. Popma, Vinod H. Thourani

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette III: Subset Analysis of Strokes

Presenter: David J. Cohen, Jeffrey J. Popma, A. Pieter Kappetein

June 16, 2017

Presentation TVT 2017

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Advertisement

Options for Aortic Stenosis and Prosthesis-Patient Mismatch: Reoperation, Fracture, Supra-annular Valve, Balloon Valvuloplasty, Other

Identifying the Futile Severe AS Patient - Who Shouldnt Be Treated With TAVR?

VAMPIRE 3: Attenuated Plaque May Signal Benefit of Thrombus Removal in PCI

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Live From Denver: TCT 2017, Day Two

No Advantage With Hybrid Revascularization for Multivessel Disease: HREVS

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Case #5: Tamponade in the Post-CABG Patient (With Discussion)

Live From Denver: TCT 2017, Day One

No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy

Episode 16: Healthcare Reform, Embolic Protection in TAVR, and More

Is the Current Practice of Watchful Waiting in Severe AS a Viable Strategy in the Future?

Rationale and Status Update of the EARLY TAVR Trial Asymptomatic Severe AS Patients

Rationale and Status Update of the TAVR UNLOAD Trial Moderate AS Patients With Reduced Ejection Fraction

A Practical Clinical Algorithm for Correctly Diagnosing and Managing Patients With Low Flow Aortic Stenosis

A Model of TAVR (vs SAVR) Case Selection, Based Solely on Clinical and Anatomic Factors

After PARTNER 2A/S3i and SURTAVI, What Is the Role of Surgery in Intermediate-Risk AS Patients?

SURTAVI Vignette III: Subset Analysis of Strokes

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content